8-K
filed October 5, 2023, 7:59 PM ET
ticker ESLA
CIK 0001844417
M&A
confidence high
sentiment positive
materiality 0.85
Estrella Immunopharma, Inc. (ESLA): M&A transaction — TradeUP Acquisition Corp completes merger with Estrella Biopharma; becomes Estrella Immunopharma, listing on Nasdaq
Estrella Immunopharma, Inc.
- Merger consideration of $325M; Estrella stockholders receive 32.5M shares; name changes to Estrella Immunopharma.
- Gross proceeds of ~$23.11M from PIPE ($10M) and Series A sales ($9.75M); funds expected to support operations into 2024.
- Officers/directors own ~92.3% of outstanding shares; former UPTD holders own ~4.8%.
- Common stock (ESLA) and warrants (ESLAW) start trading on Nasdaq on Oct 2, 2023.
- Entered into $50M equity line with White Lion Capital; 3.5M shares authorized under 2023 Incentive Plan.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Estrella Immunopharma, Inc.: New amended and restated bylaws (New Bylaws) approved and adopted by board of directors, effective as of the Effective Time (September 29, 2023) (effective 2023-09-29).
- Change
- bylaw amendment
- Effective
- 2023-09-29
Exact text from the filing
On September 29, 2023, the board of directors of New Estrella approved and adopted the New Bylaws, which became effective as of the Effective Time.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Estrella Immunopharma, Inc.: Board of directors approved and adopted a new Code of Ethics applicable to directors, officers and employees in connection with the Closing (effective 2023-09-29).
- Change
- code of ethics
- Effective
- 2023-09-29
Exact text from the filing
In connection with the Closing, the board of directors of New Estrella approved and adopted a new Code of Ethics applicable to directors, officers and employees.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Estrella Immunopharma, Inc.: Amended and restated certificate of incorporation (New Charter) approved at special meeting and effective upon filing with Secretary of State of Delaware on September 29, 2023 (effective 2023-09-29).
- Change
- charter amendment
- Effective
- 2023-09-29
Exact text from the filing
The New Charter, which became effective upon filing with the Secretary of State of the State of Delaware on September 29, 2023, includes the amendments proposed by the Charter Proposal and approved at the Special Meeting.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Estrella Immunopharma, Inc.: Upon the Closing, New Estrella ceased to be a shell company.
- Change
- shell status
Exact text from the filing
Upon the Closing, New Estrella ceased to be a shell company.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Estrella Immunopharma, Inc. underwent a change of control involving TradeUP Acquisition Corp. for $325,000,000 (closed 2023-09-29).
- Action
- change of control
- Counterparty
- TradeUP Acquisition Corp.
- Consideration
- $325,000,000
- Closing
- 2023-09-29
Exact text from the filing
from UPTD, in the aggregate, a number of newly issued shares of common stock of New Estrella (as defined below), par value $0.0001 per share (“Common Stock”) equal to: (i) $325,000,000 (the “Merger Consideration”), divided by (ii) $10.00 per share (such shares of Common Stock is referred as “Merger Consideration Shares”) in consideration of converting their
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.